Montara Therapeutics

Montara Therapeutics is a preclinical-stage biopharmaceutical company developing *BrainOnly™* brain‑selective therapies that pair a brain‑penetrant therapeutic with a universal peripheral blocker to restrict peripheral on‑target activity and improve the therapeutic index for CNS diseases[3][5].

High‑Level Overview

• Mission: Montara’s stated mission is to develop safer, more efficacious treatments for central nervous system (CNS) diseases by enabling brain‑specific pharmacology through its BrainOnly™ platform[3][5].[3][5]
  - Investment philosophy / key sectors / impact on startup ecosystem: Montara is itself a portfolio biotech (backed by investors such as Two Bear Capital, SV Health Investors’ Dementia Discovery Fund, KdT Ventures, Dolby Family Ventures and BEVC) rather than an investment firm; it operates in the neuroscience / CNS therapeutics sector and has attracted venture and disease‑focused funders, which supports continued investor interest in platform approaches to CNS drug discovery[4][2][3].[4][2][3]
  - What product it builds: Montara builds preclinical drug candidates based on the BrainOnly™ approach — two‑molecule combinations composed of a brain‑penetrant active and a universal peripheral blocker to create brain‑specific pharmacology[3][5].[3][5]
  - Who it serves: The company targets patients with neurological and neurodegenerative diseases, including rare epilepsies and age‑related neurodegenerative disorders, and partners (pharma/biotech) interested in CNS programs[3][5].[3][5]
  - What problem it solves: Montara aims to overcome the safety and tolerability limits of many CNS drugs by preventing deleterious peripheral effects, thereby enabling higher effective CNS dosing and making previously intractable targets druggable[3][5].[3][5]
  - Growth momentum: Founded in 2022, Montara rapidly achieved in vivo proof‑of‑concept and in 2025 completed an oversubscribed $20M seed expansion (bringing total seed to $28M) to advance a lead rare epilepsy program to IND and progress additional programs[1][3][2].[1][3][2]

Origin Story

• Founding year and leadership: Montara was founded in 2022 and is led by Founder & CEO Nicholas T. Hertz, Ph.D.[1][3].[1][3]
  - How the idea emerged: The company was formed to address the central challenge in CNS drug development—on‑target peripheral toxicities—by engineering a platform (BrainOnly™) that combines a brain‑penetrant therapeutic with a universal peripheral blocker to block peripheral activity and restrict efficacy to the brain[3][5].[3][5]
  - Early traction / pivotal moments: Within roughly a year Montara reported in vivo proof‑of‑concept and moved toward IND‑enabling studies; in March 2025 it closed an oversubscribed $20M seed expansion (total seed $28M) with participation from existing and new investors, and announced program advancement priorities including IND for a rare epilepsy program and progression of a Parkinson’s/LRRK2‑related program supported by Michael J. Fox Foundation collaborations[3][2][5].[3][2][5]

Core Differentiators

• Platform architecture: BrainOnly™ uses a *two‑molecule* design—pairing a brain‑penetrant active with a universal peripheral blocker—to create brain‑restricted pharmacology and reduce peripheral on‑target toxicity[3][5].[3][5]
  - Target expansion: The approach aims to make targets that were previously limited by peripheral toxicity more druggable, potentially expanding the addressable target space in CNS disease[3][5].[3][5]
  - Speed to proof‑of‑concept: The company reports rapid preclinical progress from founding to in vivo proof‑of‑concept and IND‑directed studies within ~1–2 years, a notable operational tempo for a preclinical biotech[3][5].[3][5]
  - Investor and partner endorsement: Backing from specialized investors (e.g., SV Health Investors’ Dementia Discovery Fund, Two Bear Capital) and engagement with disease foundations (e.g., Michael J. Fox Foundation initiatives) strengthens scientific and translational credibility[2][4][5].[2][4][5]

Role in the Broader Tech / Biotech Landscape

• Trend alignment: Montara rides the broader trends of precision pharmacology and targeted delivery in CNS therapeutics, where improved safety windows and brain selectivity are high priorities for both rare and common neurological indications[3][5].[3][5]
  - Why timing matters: CNS drug development has long been constrained by peripheral toxicities and low therapeutic indices; advances in medicinal chemistry and platform strategies increase feasibility for brain‑selective approaches now versus prior decades[3][5].[3][5]
  - Market forces: Large unmet clinical need in epilepsy, Parkinson’s disease, and other CNS disorders, together with rising investor interest in neuroscience platforms and foundation‑backed de‑risking programs, favor companies that can demonstrably improve safety and targetability[2][3][5].[2][3][5]
  - Influence on ecosystem: If validated clinically, a modular brain‑selective platform could become an enabling technology for pharma partnerships, accelerate CNS pipeline diversification, and shift how companies approach on‑target peripheral liabilities[3][5].[3][5]

Quick Take & Future Outlook

• Near term: Montara’s immediate objective is to advance its lead rare epilepsy program to IND and progress a second neurodegenerative candidate to development candidate status, funded by its 2025 seed expansion[3][2].[3][2]
  - Key trends that will shape the journey: Clinical validation of the BrainOnly™ concept (safety and CNS selectivity in humans), enzyme/transporter biology for peripheral blockade, and partner interest from larger pharma will determine scalability and licensing options[3][5].[3][5]
  - How influence might evolve: Successful IND filings and early clinical data demonstrating improved therapeutic index would position Montara as a platform company attractive for partnerships or acquisition, and could materially impact CNS drug design strategies by offering a generalizable solution to peripheral toxicity constraints[3][5].[3][5]

Quick reiteration: Montara Therapeutics is a 2022‑founded, San Francisco–area biotech developing brain‑selective two‑molecule therapies under the BrainOnly™ platform to enable safer, more effective CNS treatments and is progressing multiple programs toward IND with an oversubscribed 2025 seed expansion supporting those efforts[1][3][2].[1][3][2]

Notes and limitations: Public information on Montara is currently limited to company releases, investor pages, and trade coverage; clinical validation remains pending and outcome uncertainty should be expected until human data are available[3][2][4].[3][2][4]